HALO
Halozyme Therapeutics, Inc.Company with tickers: HALO
CIK
1159036
CUSIP
40637H109
Shares Outstanding
118,613,000
13F Activity (30d)
454 filings
422 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $376,708,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $25,560,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $184,517,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $150,049,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $1.27 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $1.22 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |